Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Projected fourth quarter net sales of more than $37 mil. would be firm's highest quarterly revenues ever, Salt Lake City-based supplement direct seller says Dec. 18. Stronger-than-expected results were driven by "an increased number of associate enrollments, spurred by the newly launched Taiwan market and continued growth in each of our major markets," USANA states. Firm announced plan to enter Taiwan earlier this year (1"The Tan Sheet" May 13, 2002, In Brief)...

You may also be interested in...

USANA expansion

Direct marketer's entry into Taiwan slated for Q4. Company putting infrastructure in place and obtaining product approvals, also plans to leverage existing resources in Hong Kong, Australia to support Taiwan entry. One-time costs associated with suspended effort to take direct marketer private result in Q1 earnings per share impact of 3¢, USANA says April 25. Nevertheless, net earnings rose 140% from year-ago quarter to $1.1 mil. on a 3.7% sales gain to $28.6 mil. Improved margins resulted from production efficiencies, adjustment in pricing strategy, firm explains. USANA founder Myron Wentz cited company's improved performance as reason for terminating his bid to take it private (1"The Tan Sheet" April 15, 2002, p. 5)...

COVID-19: String Of FDA Guidance Docs Lay Bare Enforcement Policies For Infusion Pumps, ECMO Devices, Thermometers, And More

In three separate immediately-in-effect guidance documents, the US agency says makers of infusion pumps and accessories, extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass devices, and remote ophthalmic assessment and monitoring devices can make “limited modifications” to those products so they can be used during the ongoing novel coronavirus crisis, without the need for firms to seek out a new 510(k). A fourth guidance says clinical electronic thermometers that aren’t yet 510(k)-cleared by the FDA can be distributed for use.

COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts